查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138312

全球癌症幹細胞市場-2022-2029

Global Cancer Stem Cells Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

影響全球癌症幹細胞市場的因素正在增加對乾細胞研究和癌症的資助，以及不斷增長的抗 CSCs 療法。

用於乾細胞研究和癌症研究的資金不斷增加預計將推動市場增長。

美國國家癌症研究所 (NCI) 是世界上最大的癌症研究資助者。根據國會的規定，研究所的年度預算約為 62.5 億美元。這些贈款有助於建立基礎設施，以繼續在 NCI 和世界各地的癌症中心、醫院、社區診所和大學進行癌症研究。

美國國家癌症研究所 (NCI) 設有多個部門和中心，負責開展研究或管理研究項目。 NCI 2020 財年的資金為 64 億美元（包括 1.95 億美元的 CURES 法案資金），比上一年增加 5.24 億美元，即 9.2%。美國癌症研究協會 (AACR) 是世界上第一個也是最大的癌症研究組織，致力於讓癌症成為過去。此外，作為美國國立衛生研究院以外幹細胞研究的最大資金來源，CIRM 贊助創新研究計劃，重點是快速將藥物提供給醫療需求未得到滿足的患者。這包括基礎研究，例如探索性研究和轉化研究，以及臨床試驗。因此，增加對癌症研究和乾細胞的資助預計將在預測期內推動市場增長。

預計在預測期內，高成本將阻礙市場增長。

細胞療法和其他再生醫學作為對現代醫學的潛在變革性貢獻而受到廣泛關注，但它們的成本很高。人口增長和老齡化已經給公共衛生支出帶來壓力，這給許多私人保險公司的預算帶來壓力。但付款人的現金流管理系統卻不是這種情況。

行業分析

癌症幹細胞市場根據各種行業因素（包括搬運工五力、供應鍊和價格分析）對市場進行了深入分析。

COVID-19 影響分析

預計幹細胞療法用於 COVID-19 將對市場增長產生積極影響。例如，抗病毒藥、抗瘧藥和抗炎藥是目前正在研究治療 COVID-19 疾病的療法之一。這些治療可以幫助患者康復並延長壽命，但它們不能完全逆轉由疾病引起的肺損傷。幹細胞療法以及最近由幹細胞釋放的細胞外囊泡 (EV) 已成為一種新型且有前景的療法，可在修復 COVID-19 肺損傷的同時減少炎症。

據推測，幹細胞通過其 EV 發揮治療作用，例如免疫調節、抗氧化和恢復作用，並且可能單獨或與其他治療藥物聯合用於 COVID-19 患者。有一種性質。目前，有 17 項臨床試驗研究 MSCs 作為 COVID-19 的治療方法，其中大部分是靜脈注射，只有一項試驗測試吸入 MSC 衍生的外泌體。因此，幹細胞治療的需求有望推動市場增長。

全球癌症幹細胞市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁內容。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 增加對乾細胞研究和癌症研究的資助有望推動市場增長。
    • 限制因素
      • 預計在預測期內，高成本將阻礙市場增長。
    • 機會
    • 影響分析

第5章行業分析

  • 波特的五種力量
  • 未滿足的需求
  • 供應鏈
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 發布前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按癌症類型

  • 血癌
  • 乳腺癌
  • 結腸癌
  • 肺癌
  • 肝癌
  • 腦腫瘤
  • 其他

第 8 章作用機制

  • 使用乾細胞治療癌症
    • 自體幹細胞移植
    • 異基因幹細胞移植
  • 針對癌症幹細胞 (CSC) 的療法
    • 通過抗癌幹細胞藥物
      • 通路抑製劑
      • WNT 信號通路
      • Hedgehog 信號通路
      • Notch 信號通路
      • 其他
      • 表面標記底座
      • 免疫逃避/腫瘤微環境靶向治療
      • 使用納米粒子進行治療
      • 其他
    • 按產品
      • 細胞培養
      • 細胞分離
      • 細胞分析
      • 分子生物學分析
      • 其他

第 9 章，最終用戶

  • 癌症治療設施
  • 醫院
  • 研究所
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • 默克公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Bionomics.
  • AbbVie, Inc.
  • Stemline Therapeutics, Inc
  • LONZA
  • PromoCell GmbH
  • Miltenyi Biotec
  • STEMCELL Technologies Inc
  • BIOTIME, Inc

第13章 全球癌症幹細胞市場-DataM

簡介目錄
Product Code: DMPH372

Market Overview

Cancer stem cells market size is estimated to reach USD million by 2029, growing at a CAGR of 6.7 % during the forecast period (2022-2029).

Cancer stem cells are uncommon immortal cells seen in tumors that give rise to a diverse range of cell types that make up the tumor. These cells have been found in a number of human malignancies and may be employed as cancer therapeutic targets.

Market Dynamics

The factors influencing the global cancer stem cells market are increasing funding for stem cell research and cancer and the growing anti-CSCs therapeutics pipeline.

Increasing funding for stem cell research and cancer research is expected to drive market growth.

The National Cancer Institute (NCI) is the world's largest funder of cancer research. The institute's annual budget is roughly $6.25 billion, as established by Congress. These grants help finance the infrastructure that allows cancer research to continue at NCI and other cancer centers, hospitals, community clinics, and colleges worldwide.

The National Cancer Institute (NCI) contains a variety of divisions and centers that perform research or manage research projects. The NCI had $6.4 billion in funds in FY 2020 (including $195 million in CURES Act funding), up 9.2 percent or $524 million from the previous fiscal year. The American Association for Cancer Research (AACR) is the world's first and biggest cancer research organization dedicated to making cancer a thing of the past. Moreover, CIRM sponsors innovative research initiatives focused on expediting medicines to patients with unmet medical needs as the largest source of financing for stem cell research outside the National Institutes of Health. This includes everything from basic research, such as discovery and translational research, to clinical trials. Hence, the increased funding for cancer research and stem cells is expected to drive market growth in the forecast period.

High costs are expected to hamper the market's growth in the forecast period.

Cellular treatments and other regenerative medicines are gaining traction as potentially transformational contributions to modern medicine but at a hefty price tag. Growing and aging populations are already straining public healthcare costs, and many commercial insurers' budgets are also being pressured. Most payers' cash-flow management systems are not.

Industry Analysis

The cancer stem cells market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis etc.

COVID-19 Impact Analysis

The use of stem cell therapies for COVID-19 is expected to positively impact market growth. For instance, antiviral, antimalarial, and anti-inflammatory drugs are among the treatments now being studied for the treatment of COVID-19 disease. While these treatments can help patients recover and live longer, they do not completely restore the lung damage caused by this disease. Stem cell therapies, and more recently, their released extracellular vesicles (EVs), are emerging as novel and promising treatments that may reduce inflammation while also repairing COVID-19-induced lung damage.

Stem cells presumably exert their immunomodulatory, anti-oxidant, and reparative therapeutic actions through their EVs, which could be useful in people with COVID-19, either alone or combined with other treatment drugs. There are currently 17 clinical trials examining MSCs for the treatment of COVID-19, most of which are administered intravenously, with just one experiment testing MSC-derived exosomes by inhalation. Hence, the demand for stem cell therapies is expected to drive market growth.

Segment Analysis

Stem Cell-based Cancer Therapy segment is expected to hold the largest market share in cancer stem cells market.

The stem cell-based cancer therapy segment accounted for the largest market share in 2021. Stem cell-based cancer therapy is further segmented into autologous SC transplants and allogeneic transplants. Stem cell transplants are treatments that help people who have had their blood-forming stem cells destroyed by heavy doses of chemotherapy or radiation therapy used to treat certain cancers. Blood-forming stem cells are crucial because they differentiate into many types of blood cells. An autologous stem cell transplant replaces diseased or damaged bone marrow with healthy blood stem cells from the recipient's body. An autologous bone marrow transplant is similar to an autologous stem cell transplant. When compared to stem cells from a donor, using cells from one's own body during a stem cell transplant has some advantages. If the body produces enough healthy bone marrow cells, an autologous stem cell transplant may be an option.

These cells can be collected, frozen, and used later. People who require severe doses of chemotherapy and radiation to cure their conditions frequently have autologous stem cell transplants. The bone marrow is likely to be damaged due to these treatments. The damaged bone marrow can be replaced with an autologous stem cell transplant. In contrast, an allogeneic stem cell transplant replaces bone marrow that isn't producing enough healthy blood cells with healthy blood stem cells from a donor. An allogeneic bone marrow transplant is similar to an allogeneic stem cell transplant.

Geographical Analysis

North American region holds the largest market share in the global cancer stem cells market

The growing prevalence of cancer and increasing R&D is expected to drive the market in this region. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed, and there will be 608,570 cancer deaths in the United States. In contrast, in 2022, roughly 1.9 million people will be diagnosed with cancer in the United States. An estimated 287,850 women and 2,710 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common overall, with 268,490 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis, with an estimated 236,740 new cases.

Moreover, although stem cell research is allowed in the United States, it is subject to funding and usage restrictions. Blood cell-forming adult stem cells found in the bone marrow are currently the only stem cells employed to treat illness. Furthermore, many companies in this region are key players, such as Thermo Fisher Scientific, AbbVie, Inc., Stemline Therapeutics, Inc, STEMCELL Technologies, Inc, and others. In addition, Gamida-Cell Ltd., a U.S.-based next-generation stem cell therapy research and development business, will begin rolling out Biologics License Application (BLA) submissions for omidubicel on January 31, 2022. Omidubicel is a bone marrow stem cell transplant clinically developed for patients with blood malignancies. Gamida-Cell Ltd. stated that the rolling submission was approved following good comments from the type B meeting with the FDA.

Competitive Landscape

Major key players in the cancer stem cells market are Merck KGaA, Thermo Fisher Scientific, Inc., Bionomics, AbbVie, Inc., Stemline Therapeutics, Inc, LONZA, PromoCell GmbH, Miltenyi Biotec, STEMCELL Technologies Inc., BIOTIME, Inc.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

Thermo Fisher Scientific provides optimized solutions for cancer stem cell research-from identification and culturing to genomic and functional analysis.

  • Attune NxT Flow Cytometer
  • Cell Health Assays
  • TaqMan Protein Expression Assay

The global cancer stem cells market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing funding for stem cell research and cancer research is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs are expected to hamper the market's growth in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type Segment
  • 7.2. Blood Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Liver Cancer
  • 7.7. Brain Cancer
  • 7.8. Others

8. By Mode of Action

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 8.1.2. Market Attractiveness Index, By Mode of Action Segment
  • 8.2. Stem Cell-based Cancer Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Autologous Stem Cell Transplant
    • 8.2.4. Allogeneic Stem Cell Transplant
  • 8.3. Targeted Cancerous Stem Cells (CSCs)
    • 8.3.1. By Anti-Cancer Stem Cell Therapeutics
      • 8.3.1.1. Pathway Inhibitors
      • 8.3.1.1.1. WNT Signaling Pathway
      • 8.3.1.1.2. Hedgehog Signaling Pathway
      • 8.3.1.1.3. Notch Signaling Pathway
      • 8.3.1.1.4. Others
      • 8.3.1.2. Surface Marker-based
      • 8.3.1.3. Immuno-evasion & Targeting Tumor Microenvironment
      • 8.3.1.4. Nanoparticle-based Therapies
      • 8.3.1.5. Others
    • 8.3.2. By Products
      • 8.3.2.1. Cell Culturing
      • 8.3.2.2. Cell Separation
      • 8.3.2.3. Cell Analysis
      • 8.3.2.4. Molecular Analysis
      • 8.3.2.5. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Specialised Cancer Treatment Centers*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Hospitals
  • 9.4. Research Institutes
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Merck KGaA*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. Thermo Fisher Scientific, Inc.
  • 12.4. Bionomics.
  • 12.5. AbbVie, Inc.
  • 12.6. Stemline Therapeutics, Inc
  • 12.7. LONZA
  • 12.8. PromoCell GmbH
  • 12.9. Miltenyi Biotec
  • 12.10. STEMCELL Technologies Inc
  • 12.11. BIOTIME, Inc

LIST NOT EXHAUSTIVE

13. Global Cancer Stem Cells Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us